Abstract
Transplantation of hepatocytes, whether genetically modified or not, has become an alternative to orthotopic liver transplantation for the treatment of patients with metabolic disease. However, more than ten years after the first clinical trial of ex vivo gene therapy to treat patients with Familial Hypercholesterolemia, there are still a number of impediments to these approaches. Numerous animal models are still being developed on the one hand to improve hepatocyte integration within hepatic parenchyma and function, and on the other hand to develop vectors that drive long-term transgene expression in situ. These include large animal models such as non-human primates, which have recently led to significant progress in hepatocyte transplantation. Simultaneous development of lentiviral vectors from different lentivirus species has permitted the transfer of genes into mitotically-quiescent primary cells including differentiated hepatocytes. Particularly third generation vectors derived from HIV-1 lentivirus are the most widely used and have significantly improved the safety and efficiency of these vectors. Given the shortage of organs and problems related to immunosuppression on one hand, and recent progresses in hepatocyte transduction and transplantation on the other hand, ex vivo approach is becoming a real alternative to allogeneic hepatocyte transplantation. We review the present progresses and limits of the ex vivo liver gene therapy approach in different animal models, emphasizing clinically relevant procedures.
Keywords: Liver disease, gene therapy, lentiviral vectors, animal models
Current Gene Therapy
Title: Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Volume: 9 Issue: 2
Author(s): Tuan Huy Nguyen, Sylvie Mainot, Panagiotis Lainas, Marie-Therese Groyer-Picard, Dominique Franco, Ibrahim Dagher and Anne Weber
Affiliation:
Keywords: Liver disease, gene therapy, lentiviral vectors, animal models
Abstract: Transplantation of hepatocytes, whether genetically modified or not, has become an alternative to orthotopic liver transplantation for the treatment of patients with metabolic disease. However, more than ten years after the first clinical trial of ex vivo gene therapy to treat patients with Familial Hypercholesterolemia, there are still a number of impediments to these approaches. Numerous animal models are still being developed on the one hand to improve hepatocyte integration within hepatic parenchyma and function, and on the other hand to develop vectors that drive long-term transgene expression in situ. These include large animal models such as non-human primates, which have recently led to significant progress in hepatocyte transplantation. Simultaneous development of lentiviral vectors from different lentivirus species has permitted the transfer of genes into mitotically-quiescent primary cells including differentiated hepatocytes. Particularly third generation vectors derived from HIV-1 lentivirus are the most widely used and have significantly improved the safety and efficiency of these vectors. Given the shortage of organs and problems related to immunosuppression on one hand, and recent progresses in hepatocyte transduction and transplantation on the other hand, ex vivo approach is becoming a real alternative to allogeneic hepatocyte transplantation. We review the present progresses and limits of the ex vivo liver gene therapy approach in different animal models, emphasizing clinically relevant procedures.
Export Options
About this article
Cite this article as:
Nguyen Huy Tuan, Mainot Sylvie, Lainas Panagiotis, Groyer-Picard Marie-Therese, Franco Dominique, Dagher Ibrahim and Weber Anne, Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors, Current Gene Therapy 2009; 9 (2) . https://dx.doi.org/10.2174/156652309787909481
DOI https://dx.doi.org/10.2174/156652309787909481 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Gold Nanoparticle-Based Drug Delivery Platform for Antineoplastic Chemotherapy
Current Drug Metabolism Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Editorial [Hot Topic: Herpes Simplex Virus Type 1-Based Amplicons Vectors (Guest Editor: Alberto L. Epstein)]
Current Gene Therapy A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Bone Regeneration and Repair
Current Stem Cell Research & Therapy Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Deglucohellebrin: A Potent Agent for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design